Morphine News and Research

Latest Morphine News and Research

Drugs blocking the effects of ACh may prevent cancer

By seeing what substances and molecules affect the development of our diseases, we can develop drugs that prevent or cure diseases. In her dissertation at Kalmar University in Sweden, Ann Novotny has found that the signal molecule acetylcholine (ACh) is important for the progress of cancer of the large intestine and colon, knowledge that is important to factor in when developing drugs that block the effects of Ach on tumor cells.

23 Sep 2009

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

King Pharmaceuticals(R), Inc. (NYSE: KG) today announced a true milestone as it marks the first commercial availability for EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

21 Sep 2009

Adolescents are less susceptible to drug withdrawal than adults

As part of efforts to understand drug abuse, Georgia State University researchers are finding that adolescent rats appear to be less vulnerable to the long-term effects of withdrawal and relapse in certain types of drug use than rats that take the drugs in adulthood.

17 Sep 2009

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

9 Sep 2009

PROTECT clinical study aimed at the assessment of rolofylline effects

Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.

2 Sep 2009

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its recently launched pain reliever, Cobroxin, was selected as the “Best New Product” at the Efficient Collaborative Retail Marketing (ECRM) Conference. Cobroxin was chosen as the award recipient by conference attendees, including several of the leading national retailers.

31 Aug 2009

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

27 Aug 2009

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

QRxPharma Limited and announced today successful completion of its pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients with moderate to severe pain following total knee replacement surgery.

27 Aug 2009

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Cobroxin, an over-the-counter (OTC) treatment for stage 2 (moderate to severe) chronic pain.

25 Aug 2009

Nutra Pharma launches Cobroxin for chronic pain relief

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has launched an over-the-counter (OTC) pain reliever, Cobroxin, for the treatment of Stage 2 (moderate to severe) chronic pain.

21 Aug 2009

Traditional Chinese acupuncture affects the brain's long-term ability to regulate pain

Acupuncture has been used in East-Asian medicine for thousands of years to treat pain, possibly by activating the body's natural painkillers. But how it works at the cellular level is largely unknown.

10 Aug 2009

Compound from coral offers hope fpr neuropathic pain

A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system.

4 Aug 2009

Adding a drug called neostigmine to epidural analgesia reduces dose needed during labor

Adding a drug called neostigmine to epidural analgesia during labor can reduce the amount of anesthetic drug required, while avoiding potential complications caused by morphine-like "opioid" drugs, according to a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

27 Jul 2009

Study may lead to new drugs to treat cough

Scientists investigating the cough reflex have discovered a new group of molecules on the surface of nerve cells that make us cough when irritated.

9 Jul 2009

Local anaesthetic reduces need for painkillers post-Caesarean section

Giving a local anaesthetic during a Caesarean section helps manage pain after the operation and can reduce consumption of painkillers, according to Cochrane Researchers. The researchers recommend local anaesthetics as part of integrated pain management strategies for Caesarean section operations, provided that consideration is given to the cost.

7 Jul 2009

Local anaesthetic during a Caesarean section reduces need for painkillers post-op

7 Jul 2009

The surprising effect of cannabis on morphine dependence

Injections of THC, the active principle of cannabis, eliminate dependence on opiates (morphine, heroin) in rats deprived of their mothers at birth. This has been shown by a study carried out by Valérie Daugé and her team at the Laboratory for Physiopathology of Diseases of the Central Nervous System (UPMC / CNRS / INSERM) in the journal Neuropsychopharmacology. The findings could lead to therapeutic alternatives to existing substitution treatments.

6 Jul 2009

FDA approves injectable Ibuprofen

The U.S. Food and Drug Administration today approved Caldolor, the first injectable dosage form of the common pain medication ibuprofen, to treat pain and fever.

11 Jun 2009

Study offers new insights into morphine-induced tolerance and increased pain sensitivity

A study published in the June issue of Anesthesiology has shown that a drug metabolite of the opioid morphine may be a key factor in the paradoxical increased sensitivity to pain caused by chronic morphine use. For the first time, this metabolite (called morphine-6 glucuronide, or M6G) was shown to act independently of the pain receptors typically targeted during morphine administration.

21 May 2009

Morphine patches create addiction

Morphine patches are supposed to reduce use of painkillers, and provide more control over their use in chronic pain conditions. But researchers at the Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital in Trondheim have found otherwise.

15 May 2009

Morphine News and Research

Latest Morphine News and Research

Drugs blocking the effects of ACh may prevent cancer

King Pharmaceuticals achieves milestone: Announces commercial availability of EMBEDA

Adolescents are less susceptible to drug withdrawal than adults

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals

PROTECT clinical study aimed at the assessment of rolofylline effects

Nutra Pharma’s Cobroxin pain reliever is "Best New Product" at the ECRM Conference

XenaCare Holdings to market Cobroxin pain reliever drug in U.S.

QRxPharma completes its pilot evaluation study investigating the efficacy of MoxDuo capsules

Nutra Pharma submits final packaging and labeling for Cobroxin drug for FDA approval

Nutra Pharma launches Cobroxin for chronic pain relief

Traditional Chinese acupuncture affects the brain's long-term ability to regulate pain

Compound from coral offers hope fpr neuropathic pain

Adding a drug called neostigmine to epidural analgesia reduces dose needed during labor

Study may lead to new drugs to treat cough

Local anaesthetic reduces need for painkillers post-Caesarean section

Local anaesthetic during a Caesarean section reduces need for painkillers post-op

The surprising effect of cannabis on morphine dependence

FDA approves injectable Ibuprofen

Study offers new insights into morphine-induced tolerance and increased pain sensitivity

Morphine patches create addiction

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Morphine News and Research

Latest Morphine News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in